Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

779.67 -2.71 (-0.35%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

49 50 Next >

Regeneron Pharmaceuticals: Q3 Earnings Insights ↗

November 03, 2022

Regeneron Pharmaceuticals (NASDAQ:REGN) reported its Q3 earnings results on Thursday, November 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Regeneron Pharmaceuticals Unusual Options Activity ↗

November 02, 2022

A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 15 strange...

Via Benzinga

Here's How Much $1000 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth Today ↗

November 02, 2022

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 21.24% on an annualized basis producing an average annual return of 27.82%. Currently, Regeneron...

Via Benzinga

Midterm Elections 2022: 3 Stocks to Avoid Like the Plague for a ‘Blue Wave’ ↗

October 27, 2022

If you see a blue wave coming get out of the oilpatch, crypto, and pharmaceuticals that are subject to price regulation.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022 ↗

October 26, 2022

Upgrades

Via Benzinga

Analyst Ratings for Regeneron Pharmaceuticals ↗

October 17, 2022

Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings within the last quarter:

Via Benzinga

Earnings Scheduled For November 3, 2022 ↗

November 03, 2022

Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022 ↗

November 01, 2022

Upgrades

Via Benzinga

Cytokinetics CEO: Why It's OK Not Being An Overnight Success ↗

October 25, 2022

The company hopes to come out next year with at least one heart-failure drug.

Via Investor's Business Daily

Analyst Ratings for Regeneron Pharmaceuticals ↗

October 03, 2022

Within the last quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings:

Via Benzinga

October 25, 2022

Via The Motley Fool

CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures? ↗

October 20, 2022

Despite enthusiasm in some camps, the risk of potential cures clouds market projections.

Via Investor's Business Daily

2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗

October 18, 2022

These two durable companies can navigate the market downturn and beyond.

Via The Motley Fool

Steady As She Goes With Healthcare Stocks ↗

October 17, 2022

Favorable seasonality lies ahead for Q4 with a caveat of Q3 earnings reports.

Via Talk Markets

If You Invested $100 In This Stock 20 Years Ago, You Would Have $5,000 Today ↗

October 17, 2022

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 14.25% on an annualized basis producing an average annual return of 21.62%. Currently, Regeneron...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2022 ↗

October 17, 2022

Upgrades

Via Benzinga

13 Analysts Have This to Say About Regeneron Pharmaceuticals ↗

October 17, 2022

Over the past 3 months, 13 analysts have published their opinion on Regeneron Pharmaceuticals (NASDAQ:REGN) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Why Cash-Rich Companies And #ETFs Are Beating The Market? ↗

October 15, 2022

Investors believe that “cash is king” in the current environment of surging inflation, rising rates, and a potential economic downturn. ETFs that hold cash-rich companies have seen a lot of interest...

Via Talk Markets

3 Red-Hot Stocks That Could Continue to Beat the Market ↗

October 13, 2022

Investors are betting on these companies' revenue growth prospects.

Via The Motley Fool

Sanofi - Regeneron Tout Additional Positive Data From Flagship Dupixent Product ↗

October 11, 2022

Via Benzinga

Moderna, Eli Lilly And This Biotechnology Stock Insiders Are Selling ↗

October 10, 2022

The Nasdaq Composite tumbled by more than 400 points on Friday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

These 7 Biotech Stocks Are Set to Boom in 2023 ↗

October 10, 2022

This article looks at seven biotech stocks that look like good options to move significantly higher in 2023

Via InvestorPlace

2 Top Healthcare Stocks to Buy Right Now ↗

October 08, 2022

Healthcare is about as sticky of a business model as you'll find.

Via The Motley Fool

Eaton, Wynn Resorts, Lamar Advertising And This Pharma Company Are CNBC's Final Trades ↗

October 06, 2022

On CNBC’s “Halftime Report Final Trades,” Kevin O'Leary, known as "Mr. Wonderful," chose Lamar Advertising Co. (NASDAQ: LAMR).

Via Benzinga

Apple Short Sellers Made $2B In Profits In September, And Shorts In This Biotech Stock Lost $307M ↗

October 05, 2022

The SPDR S&P 500 ETF Trust (NYSE: SPY) struggled in September, historically its worst month of the year.

Via Benzinga

Large Cap Biopharmaceuticals: Core Holdings For Your Portfolio ↗

October 03, 2022

Now that some clarity is apparent for drug pricing legislation you should have a few large-cap biopharmaceutical stocks in your portfolio.

Via Talk Markets

13 Analysts Have This to Say About Regeneron Pharmaceuticals ↗

October 03, 2022

Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings within the last quarter:

Via Benzinga

Regeneron Pharmaceuticals Whale Trades For October 03 ↗

October 03, 2022

Someone with a lot of money to spend has taken a bearish stance on Regeneron Pharmaceuticals (NASDAQ:REGN). And retail traders should know. We noticed this today when the big position showed up on...

Via Benzinga

What 13 Analyst Ratings Have To Say About Regeneron Pharmaceuticals ↗

October 03, 2022

Within the last quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings:

Via Benzinga

Hopeful Golden Cross Forms On Regeneron Pharmaceuticals's Chart ↗

October 03, 2022

If history is any guide, there may be good fortune ahead for shares of Regeneron Pharmaceuticals (NASDAQ:REGN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be...

Via Benzinga

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

49 50 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Regeneron Pharmaceuticals (NQ:REGN)

Headline News about Regeneron Pharmaceuticals

Starting at $3.75/week.

Subscribe Today